Sulfa preparation for animal mastitis



Patented Nov. 9, 1948 s TATE-s y e-FFi cs SULFA PREPARfiTtlTGN FORA'NIMAE MASTITIS DonaldG. Perkins, Chestcrtjown,1Md passigriorto E. R.Squibb & Sons, N'e'wYoikfiNL Y1, 'rawcor' poration of New York F SerialNo. 387,485.

3 Claims. Cl.;.167-1--f-'51i5 This application is a division of myapplication Serial No, 387,485, filed April 8, 1941, now aban cloned.

This invention relates to, and has for its object the provision of,preparations for the treatment of animal (especially bovine) mastitis,and a method of treating this disease.

Animal mastitis is a chronic infectious disease of the mammary glands ofanimals, especially prevalent in dairy cattle, and generally caused byinfection with Streptococcus agalactz'ae. A variety of medicinal agentsand methods of treatment have been employed in the treatment of thisdisease, but the results have been discouraging; and it has beengenerally agreed that animal mastitis is intractable.

It has been found that animal mastitis may be effectively treated bydirect injection of a preparation essentially comprising a medicinalagent for animal mastitis carried by a substantially waterimmiscibleliquid having a specific gravity less than that of the treated animals mlk. [By direct injection is' meant infusion into the mi ked-out,functioning mammary gland] The direct injection of a su pension ofcolloidal silver ox de in m neral oil, for example. has been found to beexceptionally effective in the treatment of bovine (streptococcic) mastt s.

It is believed that the effectiveness of the preparations and method oftreatment of this invention is due to the particular type of carrierused. Thus. by virtue of its specific gravity, the carrier releases itsmedicinal agent while passing up through, and riding on, the milk comingdown through the mammary gland; and the medicinal agent is therebydispersed throughout the affected tissues; and this dispersion enablesthe use of a materially smaller infusion than heretofore employed. It isnot intended, however. that the invention be limited by any theoreticalexplanation.

Any medicinal agent adapted for the treatment of animal mastitis bydirect injection (i. e., any animal-m-astitis-bactericide) may be usedin the preparations of this invention: inter alia, the sc -called.bactericides (especially streptococcicides), biological products havingbactericidal effect (c. g., bacteriophages), and chemotherapeutic agents(especially of the sulfanilamide type). Among the utilizablestrebtococcicides are the acridine derivatives (e. g., rivanol andacriflavine) and especially colloidal silver oxide. As

the carrier, one may use any substantially Waterimmiscibleliquid havinga specific gravityless than that of the milk (and, of course,non-reactive with 'the'medicinal agent) Preferably, the carrier is anoil (vegetable, animal, or mineral) having 'a specific gravitymaterially less than 1; e. g., olive oil, peanut oil, or liquidpctrolatum. Mineral oil is an especially desirable carrier because it isinert and non-irritating to the mammary-gland tissues.

The medicinal agent may be directly embodied in the carrier (i. e.,dissolved or suspended therein), or indirectly embodied in the carrier,as by incorporating in the carrier a solution, emulsion, or suspensionof the medicinal agent in some other medium. The carrier and/or thefinished preparation may be sterilized.

The invention is illustrated by the following specific exampledescribing the production of a suspension of colloidal silver oxide (ofextremely small particle size) in mineral oil, and the treatment ofbovine mastitis therewith:

A suspension of colloidal silver xide in mineral oil is prepared in aknown manner for obtaining extremely small particle size, e. g., byincorporating finely-divided silver oxide in mineral oil andmechanically reducing the silver oxide panticles to colloidal size (asby passing the mixture through a colloid mill and further subjecting itto dispersion in a pebble mill). The suspension should preferablycontain about 5% silver oxide.

Milk samples from abnormal quarters of cows are subjected to laboratoryculture tests to establish the disease as bovine mastitis and identifythe type of organism causing it. The suspected cows are segregated, orat least kept at the end of the mi king line. If the quarter is swollenor inflamed, this condition is reduced before starting treatment.

The infected quarter is milked out and stripped, and the outside of thequarter is washed and treated with antiseptic solution. The suspensionof colloidal silver oxide in mineral oil is shaken thoroughly to insurecomplete admixture and (preferably) its temperature is adjusted tosubstantially body temperature. Ten cc. of the preparation is drawn intoa syringe and injected through the teat canal into the infected quarter,any material in the canal being Worked up into the milk cistern byholding the end of the-teat with the fingers of one hand and pressingup- Ward with the fingers of the other hand. Then the base of the teatis grasped and the entire quarter palpitated upward into itself severaltimes to distribute the preparation in the udder tissue.

The treated quarters are milked out with the others at regular milkingtime, and the treatment is repeated at least once in 72 hours (cases oflong standing may need 3, or even 4, injections, 72 hours apart). Aftereach injection, swelling and tenderness of the treated quarter follows,With a thick, stringy, grayish-green exudate. These symptoms usuallysubside within 2 or 3 days after each injection. Ten days to two weeksafter treatment, milk samples of the cows are again subjected tolaboratory culture tests to establish freedom from the disease.

The conditions of the treatment may be varied considerably; thus 2 to10% suspensions of colloidal silver oxide may be injected 1 to 5 timesin quantities of 5 to 20 cc. and at intervals of 12 to '72 hours; butthe conditions of the foregoing example are preferred.

The invention may be variously otherwise embodied within the scope ofthe appended claims.

I claim:

1. A composition for the treatment of bovine mastitis by directinjection consisting of a homogegiized mixture of a sulfa drug in liquidpetrola um.

2. A preparation for the treatment of animal mastitis by directinjection essentially comprising a colloidized suspension of achemotherapeutic agent of the sulfanilamide type in mineral oil.

3. A preparation for the treatment of bovine mastitis by directinjection essentially comprising a colloidized suspension ofsulfanilamide in mineral oil.

DONALD G. PERKINS.

REFERENCES CITED The following references are of record in the file ofthis patent:

UNITED STATES PATENTS Number Name Date 2,238,973 Climenko Apr. 22, 1941OTHER REFERENCES Sheehan, Medical Record, vol. 152, Sept. 4, 1940,

page 166.

